Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > COL4A3BP(Gene name) > Human
  • Add your favorite
  • COL4A3BP (Gene name),
  • Collagen type IV alpha-3-binding protein (Protein name ),  C43BP_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    COL4A3BP(CERT;STARD11);
    Protein name:
    Collagen type IV alpha-3-binding protein;
    Alternative:
    Goodpasture antigen-binding protein(GPBP);Ceramide transfer protein(hCERT);StAR-related lipid transfer protein 11;START domain-containing protein 11(StARD11);
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Interacts with COL4A3. Interacts with VAPA and VAPB. Interaction with VAPB is less efficient than with VAPA.
    Function:
    May mediate the intracellular trafficking of ceramide in a non-vesicular manner.
    Subcellular Location:
    Cytoplasm Golgi apparatus Endoplasmic reticulum Preferentially localized to the Golgi apparatus.
    Protein Attributes:
    Sequence length:
    624
    Sequence:
    50:
    MSDNQSWNSS | GSEEDPETES | GPPVERCGVL | SKWTNYIHGW | QDRWVVLKNN | 
    100:
    ALSYYKSEDE | TEYGCRGSIC | LSKAVITPHD | FDECRFDISV | NDSVWYLRAQ | 
    150:
    DPDHRQQWID | AIEQHKTESG | YGSESSLRRH | GSMVSLVSGA | SGYSATSTSS | 
    200:
    FKKGHSLREK | LAEMETFRDI | LCRQVDTLQK | YFDACADAVS | KDELQRDKVV | 
    250:
    EDDEDDFPTT | RSDGDFLHST | NGNKEKLFPH | VTPKGINGID | FKGEAITFKA | 
    300:
    TTAGILATLS | HCIELMVKRE | DSWQKRLDKE | TEKKRRTEEA | YKNAMTELKK | 
    350:
    KSHFGGPDYE | EGPNSLINEE | EFFDAVEAAL | DRQDKIEEQS | QSEKVRLHWP | 
    400:
    TSLPSGDAFS | SVGTHRFVQK | PYSRSSSMSS | IDLVSASDDV | HRFSSQVEEM | 
    450:
    VQNHMTYSLQ | DVGGDANWQL | VVEEGEMKVY | RREVEENGIV | LDPLKATHAV | 
    500:
    KGVTGHEVCN | YFWNVDVRND | WETTIENFHV | VETLADNAII | IYQTHKRVWP | 
    550:
    ASQRDVLYLS | VIRKIPALTE | NDPETWIVCN | FSVDHDSAPL | NNRCVRAKIN | 
    600:
    VAMICQTLVS | PPEGNQEISR | DNILCKITYV | ANVNPGGWAP | ASVLRAVAKR | 
    624:
    EYPKFLKRFT | SYVQEKTAGK | PILF
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    String:
    Pfam:
    SMR:
    KEGG:
    MIM:
    Uniprot:
     
    FOR
    ELISA Kit for Human Collagen type IV alpha-3-binding protein
    MSDS:
    Please sign in first.
    ELISA Kit for Human Collagen type IV alpha-3-binding protein
    Cat.:
    E14005m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    ELISA Kit for Human Collagen type IV alpha-3-binding protein
    Cat.:
    E14005h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Collagen type IV alpha-3-binding protein
    Cat.:
    U14005h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Collagen type IV alpha-3-binding protein
    Cat.:
    U14005m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Collagen type IV alpha-3-binding protein
    MSDS:
    Please sign in first.
    Polyclonal Antibody for Human Collagen type IV alpha-3-binding protein
    Polyclonal Antibody for Human Collagen type IV alpha-3-binding protein
    Polyclonal Antibody for Human Collagen type IV alpha-3-binding protein
    Monoclonal Antibody for Human Collagen type IV alpha-3-binding protein
    Monoclonal Antibody for Human Collagen type IV alpha-3-binding protein
    Monoclonal Antibody for Human Collagen type IV alpha-3-binding protein
    Protein for Human Collagen type IV alpha-3-binding protein
    Protein for Human Collagen type IV alpha-3-binding protein
    Protein for Human Collagen type IV alpha-3-binding protein

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    s

    s
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤5.2%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.4%

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Recovery was determined by spiking various levels of COL4A3BP into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    94-105

    Plasma

    100

    96-107

     

     

     

     

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of COL4A3BP and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    96-103%

    90-108%

    95-105%

    92-107%

    EDTA plasma(n=5)

    93-106%

    92-107%

    94-108%

    91-110%

    heparin plasma(n=5)

    95-105%

     

    96-104%

    97-105%

    93-109%

     

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen."
      Raya A. , Revert F. , Navarro S. , Saus J.
      J. Biol. Chem.274:12642-12649(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1);CHARACTERIZATION
    2. 2.
      "Goodpasture antigen-binding protein, the kinase that phosphorylates the Goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis."
      Raya A. , Revert-Ros F. , Martinez-Martinez P. , Navarro S. , Rosello E. , Vieites B. , Granero F. , Forteza J. , Saus J.
      J. Biol. Chem.275:40392-40399(2000) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2)
    3. 3.
      "Molecular machinery for non-vesicular trafficking of ceramide."
      Hanada K. , Kumagai K. , Yasuda S. , Miura Y. , Kawano M. , Fukasawa M. , Nishijima M.
      Nature426:803-809(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2);FUNCTION;DOMAIN;SUBCELLULAR LOCATION
    4. 4.
      "Complete sequencing and characterization of 21,243 full-length human cDNAs."
      Ota T. , Suzuki Y. , Nishikawa T. , Otsuki T. , Sugiyama T. , Irie R. , Wakamatsu A. , Hayashi K. , Sato H. , Nagai K. , Kimura K. , Makita H. , Sekine M. , Obayashi M. , Nishi T. , Shibahara T. , Tanaka T. , Ishii S. , more...
      Nat. Genet.36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3)
      tissue: Lung.
      tissue: Synovium.
    5. 6.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    6. 7.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)
      tissue: Placenta.
    7. 8.
      "Homo sapiens genomic sequence, containing DINB1 and GPBP gene."
      Ogi T. , Yamamoto Y. , Ohmori H.
      Submitted (2000-01) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-77
    8. 9.
      "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks."
      Olsen J.V. , Blagoev B. , Gnad F. , Macek B. , Kumar C. , Mortensen P. , Mann M.
      Cell127:635-648(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    9. 10.
      "Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT."
      Kawano M. , Kumagai K. , Nishijima M. , Hanada K.
      J. Biol. Chem.281:30279-30288(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH VAPA AND VAPB;SUBCELLULAR LOCATION;MUTAGENESIS OF ASP-324
    10. 11.
      "Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein."
      Fugmann T. , Hausser A. , Schoeffler P. , Schmid S. , Pfizenmaier K. , Olayioye M.A.
      J. Cell Biol.178:15-22(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION AT SER-132;FUNCTION;MUTAGENESIS OF SER-132
    11. 12.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    12. 13.
      "Casein kinase I{gamma}2 down-regulates trafficking of ceramide in the synthesis of sphingomyelin."
      Tomishige N. , Kumagai K. , Kusuda J. , Nishijima M. , Hanada K.
      Mol. Biol. Cell20:348-357(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION BY CSNK1G2/CK1
    13. 14.
      "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."
      Mayya V. , Lundgren D.H. , Hwang S.-I. , Rezaul K. , Wu L. , Eng J.K. , Rodionov V. , Han D.K.
      Sci. Signal.2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Leukemic T-cell.
    14. 15.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
    15. 16.
      "Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide."
      Kudo N. , Kumagai K. , Tomishige N. , Yamaji T. , Wakatsuki S. , Nishijima M. , Hanada K. , Kato R.
      Proc. Natl. Acad. Sci. U.S.A.105:488-493(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 347-624 IN COMPLEXES WITH CERAMIDES AND DIACYLGLYCEROL;MUTAGENESIS OF GLU-472; GLN-493 AND ASN-530;FUNCTION;SUBCELLULAR LOCATION
    16. 17.
      "Crystal structures of the CERT START domain with inhibitors provide insights into the mechanism of ceramide transfer."
      Kudo N. , Kumagai K. , Matsubara R. , Kobayashi S. , Hanada K. , Wakatsuki S. , Kato R.
      J. Mol. Biol.396:245-251(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 347-624 IN COMPLEXES WITH CERAMIDE AND INHIBITOR;MUTAGENESIS OF TRP-499;FUNCTION
    17. 18.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CYS-138
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a Gdf5
    Top Searches
    Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Tumor necrosis Alpha Asprosin TRAP1A
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    鄂ICP备10015095号-1

    鄂公网安备 42018502005535号

    Twitter